Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

4 terminated/withdrawn out of 22 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

27%

6 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed trials have results

Key Signals

5 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

8(38.1%)

Phase 1

6(28.6%)

Phase 4

4(19.0%)

Phase 3

2(9.5%)

N/A

1(4.8%)

21Total

Phase 2(8)

Phase 1(6)

Phase 4(4)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT07417124Phase 1Recruiting

Assess the Safety and Tolerability of SNS851 in Healthy Participants

Role: lead

NCT05135130Completed

Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer

Role: lead

NCT05008965Phase 2Recruiting

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

Role: lead

NCT05018299Phase 2Recruiting

Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

Role: lead

NCT06397911Phase 2Recruiting

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06531512Phase 2Recruiting

Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

Role: lead

NCT05677893Phase 1Completed

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Role: lead

NCT04962139Phase 3Terminated

Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Role: lead

NCT05322525Phase 4Terminated

A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.

Role: lead

NCT05941793Phase 2Completed

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

Role: lead

NCT05438251Phase 4Terminated

Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)

Role: lead

NCT05317442Phase 4Terminated

Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound

Role: collaborator

NCT05338463Phase 4Completed

Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients

Role: collaborator

NCT05952986Phase 1Unknown

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Role: lead

NCT02347228Phase 1Unknown

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

Role: lead

NCT04945161Not ApplicableCompleted

A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs.

Role: lead

NCT05059509Phase 2Completed

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

Role: lead

NCT04413942Phase 2Unknown

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

Role: lead

NCT01898923Phase 3Completed

Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Role: lead

NCT03890302Phase 1Completed

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Role: collaborator